Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B …
A Younes, LH Sehn, P Johnson, PL Zinzani… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell
lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus …
lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus …
Sociodemographic and clinical factors associated with radiation treatment nonadherence and survival among rural and nonrural patients with cancer
Purpose Cancer treatment nonadherence is associated with higher rates of cancer
recurrence and decreased survival. Rural patients with cancer experience a 10% higher …
recurrence and decreased survival. Rural patients with cancer experience a 10% higher …
[HTML][HTML] Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a …
S Le Guyader-Peyrou, S Orazio, O Dejardin… - …, 2017 - ncbi.nlm.nih.gov
The survival of patients with diffuse large B-cell lymphoma has increased during the last
decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although …
decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although …
[HTML][HTML] Using ecological socioeconomic position (SEP) measures to deal with sample bias introduced by incomplete individual-level measures: inequalities in breast …
S Lamy, F Molinié, L Daubisse-Marliac… - BMC Public Health, 2019 - Springer
Background When studying the influence of socioeconomic position (SEP) on health from
data where individual-level SEP measures may be missing, ecological measures of SEP …
data where individual-level SEP measures may be missing, ecological measures of SEP …
Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma
Y Utsu, K Takaishi, S Inagaki, H Arai, H Yuasa… - Annals of …, 2016 - Springer
Dose intensity (DI) of chemotherapy affects prognosis of diffuse large B cell lymphoma
(DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for …
(DLBCL). Myelotoxicity is the major dose-limiting toxicity (DLT) of most cytotoxic agents for …
[HTML][HTML] Factors Affecting Health-Related Quality of Life among Survivors of Non-Hodgkin Lymphoma: A Population-Based Study
Simple Summary Survival rates among Non-Hodgkin Lymphoma patients have significantly
improved in recent years. However, the impact of Non-Hodgkin Lymphoma persists in …
improved in recent years. However, the impact of Non-Hodgkin Lymphoma persists in …
Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health …
C Conte, M Rueter, G Laurent, R Bourrel… - Supportive Care in …, 2016 - Springer
Purpose Patients with B cell non-Hodgkin's lymphomas (B-NHLs) are known to be at risk of
developing psychological disorders. The aims of this study were to measure the incidence of …
developing psychological disorders. The aims of this study were to measure the incidence of …
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma
M Sekine, T Kameda, K Shide, K Maeda… - European Journal of …, 2021 - Wiley Online Library
Abstract Objective and Method Adult T‐cell leukemia/lymphoma (ATL) is an aggressive
peripheral T‐cell lymphoma with poor prognosis. We retrospectively reviewed the medical …
peripheral T‐cell lymphoma with poor prognosis. We retrospectively reviewed the medical …
Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic …
L Ysebaert, M Larcher, G Compaci, L Oberic… - Annals of …, 2019 - Springer
Delivering of> 80% planned relative dose intensity (RDI) of fludarabine-cyclophosphamide-
rituximab (FCR) is key to benefit from longer progression free survival (PFS) and survivals in …
rituximab (FCR) is key to benefit from longer progression free survival (PFS) and survivals in …
[HTML][HTML] Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients
M Devaux, M Boulin, M Mounier, D Caillot, N Ahwij… - Cancers, 2022 - mdpi.com
Simple Summary The treatment of Hodgkin and non-Hodgkin lymphoma is mainly based on
highly haematotoxic chemoimmunotherapy regimens that can cause serious adverse events …
highly haematotoxic chemoimmunotherapy regimens that can cause serious adverse events …